头孢哌酮/舒巴坦治疗下呼吸道感染的疗效分析  

Efficacy and safety analysis on cefoperazone/sulbactam in the treatment of lower respiratory infections in ICU

作　　者：李学军[1] 亓秀静[1] 杨逢永[1] 

机构地区：[1]莱芜市人民医院重症医学科,山东莱芜271100

出　　处：《中华医院感染学杂志》2014年第16期3961-3963,共3页Chinese Journal of Nosocomiology

基　　金：山东省莱芜市科技局基金资助项目(YYLX2012019)

摘　　要：目的观察重症监护病房下呼吸道感染患者的用药及治疗情况,分析注射用头孢哌酮/舒巴坦的疗效及安全性,为临床资料提供参考依据。方法收集2012年3月-2013年5月共63例下呼吸道感染患者,随机分为A组31例和B组32例;A组在对症治疗的基础上给予头孢哌酮治疗,B组以头孢哌酮/舒巴坦为主进行治疗,比较两组的临床有效率和病原菌清除率,对比其不良反应的发生率,数据采用SPSS15.0软件进行分析。结果 A组的临床有效率为64.5%,病原菌清除率为74.6%,临床不良反应发生率为19.4%,与之相比,B组的有效率为75.1%,病原菌清除率为93.1%,不良反应发生率为9.3%,差异有统计学意义(P<0.05)。结论注射用头孢哌酮/舒巴坦治疗重症监护病房下呼吸道感染患者能提高疗效,降低不良反应的发生率,具有广泛的有效性和安全性。OBJECTIVE To analyze the efficacy and safety of cefoperazone/sulbactam by observation of medication and treatment for patients with lower respiratory tract infections in ICU.METHODS Totally 63 patients with lower respiratory tract infections during Mar.2010 to May 2013 were randomly divided into the cefoperazone group（group A,n=31）and the cefoperazone/sulbactam group（group B,n=32）.Group A received cefoperazone in addition to the symptomatic treatment,while group B used cefoperazone/sulbactam as the primary treatment.The two groups were compared for the clinical efficiency and pathogen clearance rate,as well as the adverse reactions.Data were analyzed by SPSS 15.0software.RESULTS The clinical effective rate of group A was 64.5%,the pathogen clearance rate was 74.6%,the incidence of clinical adverse events was 19.4%.In contrast,the effective rate in group B was 75.1%,the pathogen clearance rate was 93.1%,the clinical adverse events was 9.3%,the difference was significant（P0.05）.CONCLUSION Cefoperazone/sulbactam for injection can improve efficacy of lower respiratory tract infections,reduce the occurrence of adverse events in ICU,which has broad efficacy and safety.

关 键 词：头孢哌酮 舒巴坦 下呼吸道感染 疗效 安全性 

分 类 号：R978.1[医药卫生—药品]